urban-gro, Inc. (UGRO) Q4 2023 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: negative EBITDA widening to $9.7 million, project delays, and cost revisions. Despite a 40% increase in backlog, uncertainties remain, especially with the CEA sector's underperformance. Management's vague responses on mitigating delays and capitalizing on legislative catalysts further dampen sentiment. The reduced breakeven point and diversification efforts are positives, but the overall outlook is clouded by challenges in equipment demand and European operations. Without clear guidance or a new partnership, the stock is likely to experience a negative reaction.
Key Financial Performance
Revenue Q4 2023 $15 million, a decrease of 13.5% from $17.3 million in Q4 2022. This decrease was due to reductions in all revenue categories, including construction design build revenue of $1.3 million, professional services revenue of $0.8 million, and equipment systems revenue of $0.2 million.
Gross Profit Q4 2023 $1.7 million or 11% of revenue, down from $3.2 million or 19% of revenue in Q4 2022. The decrease in gross profit of $1.5 million correlates to the decrease in revenue and a shift toward lower margin construction design build revenue.
Operating Expenses Q4 2023 $6.4 million, an increase of $0.2 million from $6.2 million in Q4 2022. The increase was due to higher general and administrative expenses, which rose by $3.8 million, offset by a $3.3 million reduction in a one-time business development expense.
Net Loss Q4 2023 $4.7 million or a negative $0.40 per diluted share, compared to a net loss of $4.2 million or a negative $0.39 per diluted share in Q4 2022.
Adjusted EBITDA Q4 2023 Negative $3 million, compared to negative $1.7 million in Q4 2022. The decrease was driven by lower revenues and gross profit, as well as an increase in general and administrative expenses.
Total Revenue FY 2023 $71.5 million, an increase of 6.7% from $67 million in FY 2022. This increase was driven by momentum in the commercial sectors, offset by decreases in equipment systems revenues.
Net Loss FY 2023 $18.7 million, compared to a net loss of $15.3 million in FY 2022.
Adjusted EBITDA FY 2023 Negative $9.7 million, compared to negative $3.9 million in FY 2022.
Cash Position at Year End 2023 $1.1 million with $2.5 million drawn on a $10 million working capital line of credit.
Backlog as of December 31, 2023 Approximately $110 million, a $26 million or 40% sequential increase over Q3 2023, attributed to delayed project delivery.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue Growth: 2023 revenues reached $72 million, a 7% increase from the previous year, with $50 million (70%) from commercial markets and $22 million (30%) from Controlled Environment Agriculture (CEA).
Backlog Increase: Total backlog as of December 31, 2023, was approximately $110 million, a 40% increase from the previous quarter, attributed to delayed project deliveries.
European Market Expansion: Urban-gro has made strategic investments in its European entity, anticipating increased demand due to early stages of adult use legislation in Germany.
Commercial Sector Growth: The commercial sector continues to show strong organic growth, supported by a qualified pipeline of projects and signed contracts.
SG&A Expense Reduction: SG&A expenses were reduced by over $8 million on an annualized basis, expected to positively impact 2024 results.
Operational Efficiency: The company optimized its size to align with current performance levels, enhancing operational efficiency.
Diversification Strategy: Urban-gro's diversification strategy is broadening its presence across multiple industries, which is reflected in the expanding backlog.
Focus on Vertical Farming: The company continues to expand its vertical farming focus, albeit at a slower pace due to capital challenges.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Project Delays: Delays across multiple projects in Q4 2023 resulted in disappointing performance, although none of the delayed contracts were lost.
Regulatory Challenges: Ongoing state-level regulatory delays in the cannabis market, including the license awarding process, have negatively impacted demand and revenue.
Market Conditions: Continued softness in the Controlled Environment Agriculture (CEA) sector has led to a significant decrease in equipment revenues, which are crucial for financial performance.
Financial Performance: A prolonged multiyear compression of equipment revenues has resulted in a 62% decrease from 2022, impacting overall profitability.
Cost Management: Increased general and administrative expenses due to legal defense costs and personnel costs, despite efforts to reduce SG&A expenses by over $8 million.
Economic Factors: The potential rescheduling of cannabis and the SAFER Banking Bill could significantly impact capital availability and market dynamics.
Backlog and Revenue Guidance: The backlog increased to $110 million, but achieving projected revenue of $84 million in 2024 is contingent on market recovery and project execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: 2024 consolidated revenues are anticipated to exceed $84 million, representing a 17% increase over 2023.
Adjusted EBITDA: Expecting to generate positive adjusted EBITDA in 2024, with a focus on reducing SG&A expenses.
Backlog: Total backlog as of December 31, 2023, is approximately $110 million, a 40% increase from Q3 2023.
Cost Reduction Initiatives: Identified over $8 million in annualized SG&A expense reductions for 2024.
Strategic Goals for Financial Services Division: 1. Improved tactical reporting for better performance visibility. 2. Drive cost reductions in insurance and facilities. 3. Strategic utilization of the line of credit.
Q1 2024 Revenue Guidance: Expecting revenues to be greater than $15 million.
Q1 2024 Adjusted EBITDA Guidance: Expecting adjusted EBITDA to be greater than negative $0.5 million.
Long-term Revenue Expectations: Majority of delayed revenues from 2023 expected to be recognized in 2024.
Market Outlook: Positive sentiment in the cannabis sector with potential regulatory changes could significantly impact future performance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: The company has not announced any share buyback or dividend program during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you expand on the project delays and cost revisions in the quarter?
A:In Q4, we had three projects that pushed back their kickoff dates, which were expected in December. One was a recreation project that we expected significant revenues from, but it also pushed back, resulting in no business completed in Q4. These projects are now active and expected to finish a quarter later than initially planned. Additionally, we had disappointing service revenue from the CEA sector, but we have better visibility now with our new ERP system.
Q:What visibility do you have on potential project delays and cost revisions impacting future quarters?
A:We do not anticipate any additional delays at this time, but we acknowledge that unexpected delays can occur. The new ERP system provides better tracking of project management, and we have a solid grasp on our services revenue.
Q:Can you provide more color on the backlog and opportunities outside the CEA?
A:Of the $110 million backlog, 70% is from the CEA sector. We are expanding into healthcare and secondary education, and we have secured over $50 million in commercial business in sectors we didn't initially target.
Q:Is the backlog expected to diversify more into CPG and healthcare?
A:Yes, the commercial projects can be completed in a shorter timeframe compared to CEA projects, and we are seeing strength in healthcare and laboratory projects.
Q:What is your outlook on the cannabis industry and potential capacity builds in key states?
A:There is positive sentiment in states like Florida, New Jersey, and Pennsylvania, but operators are cautious and waiting for regulatory clarity before committing to capacity builds.
Q:How does the SAFER Banking Act impact your pipeline projects?
A:We have a strong growing qualified pipeline that could progress once funding becomes available through the SAFER Banking Act.
Q:What is your strategy for the international markets, particularly Germany?
A:We are slowing down our operations in Germany due to market conditions but maintaining communication with potential clients. We have a strong pipeline for design builds in Europe.
Q:What is your niche in the commercial space?
A:Our niche is providing a single point of responsibility for projects under $50 million, allowing us to complete facilities quicker than traditional methods.
Q:What are you seeing in terms of equipment purchasing and potential margins?
A:Manufacturers are more willing to negotiate due to tough market conditions, and we are focusing on energy rebates to provide value to clients.
Q:What is your updated breakeven point for adjusted EBITDA?
A:The breakeven point is now around $16 million to $19 million in revenue due to G&A reductions, down from previous estimates.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the potential impact of the SAFER Banking Act on future projects, stating only that there is a strong pipeline without disclosing specific figures or timelines. Additionally, while they expressed confidence in the ability to negotiate contract revisions, they did not provide specific details on the expected outcomes or timelines for these negotiations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEA sector
Christian
ERP system
Florida
New York
SAFER Banking
SGA
Web site
access
answer
breakeven point
build project
catalyst
category
cost revision
course
day
delay cost
dispensary
effect
entity
example
expert
facility
follow
fund
guide
healthcare
issue term
kickoff
legalization
manufacturer
model
money
niche
operator
place
project delay
quarter
section Web
strength
UGRO Transcript
urban-gro, Inc. (UGRO) Q1 2024 Earnings Call Transcript
Unknown5-1
The earnings call presents a mixed picture: revenue decreased by 7% YoY, but gross profit and adjusted EBITDA improved. The cannabis industry's potential reclassification is a positive long-term catalyst, but short-term financial guidance is not strong. Operating expenses decreased significantly, yet the backlog also fell. The Q&A revealed cautious optimism about cannabis rescheduling but no immediate impact. Overall, the financial results are mixed with some positive developments, leading to a neutral sentiment.
urban-gro, Inc. (UGRO) Q4 2023 Earnings Call Transcript
Unknown3-28
The earnings call reveals several concerns: negative EBITDA widening to $9.7 million, project delays, and cost revisions. Despite a 40% increase in backlog, uncertainties remain, especially with the CEA sector's underperformance. Management's vague responses on mitigating delays and capitalizing on legislative catalysts further dampen sentiment. The reduced breakeven point and diversification efforts are positives, but the overall outlook is clouded by challenges in equipment demand and European operations. Without clear guidance or a new partnership, the stock is likely to experience a negative reaction.
urban-gro, Inc. (UGRO) Q3 2023 Earnings Call Transcript
Neutral11-12
urban-gro, Inc. (UGRO) Q2 2023 Earnings Call Transcript
Neutral8-14
UGRO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
